Mineralocorticoid resistance: Pseudohypoaldosteronism type 1;Resistência aos mineralocorticóides: Pseudo-hipoaldosteronismo tipo 1

Arquivos Brasileiros de Endocrinologia e Metabologia

Volumn 51, Issue 3, 2007, Pages 373-381

  Fernandes Rosa, Fábio L ^a   Antonini, Sonir R R ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Aldosterone; ENaC; Mineralocorticoid receptor; Type 1 pseudohypoaldosteronism

Indexed keywords

EID: 34250182768     PISSN: 00042730     EISSN: 16779487     Source Type: Journal    
DOI: 10.1590/s0004-27302007000300004     Document Type: Review

References (64)

1. Sartorato P, Lapeyraque AL, Armanini D, Kuhnle U, Khaldi Y, Salomon R, et al. Different inactivating mutations of the mineralocorticoid receptor in fourteen families affected by type I pseudohypoaldosteronism. J Clin Endocrinol Metab 2003;88(6):2508-17.
2. Geller DS. Mineralocorticoid resistance. Clin Endocrinol (Oxf) 2005;62(5):513-20.
3. Booth RE, Johnson JP, Stockand JD. Aldosterone. Adv Physiol Educ 2002;26(1-4):8-20.
4. Joels M. Corticosteroid actions in the hippocampus. J Neuroendocrinol 2001;13(8):657-69.
5. Zennaro MC, Le Menuet D, Viengchareun S, Walker F, Ricquier D, Lombes M. Hibernoma development in transgenic mice identifies brown adipose tissue as a novel target of aldosterone action. J Clin Invest 1998;101(6):1254-60.
6. Penfornis P, Viengchareun S, Le Menuet D, Cluzeaud F, Zennaro MC, Lombes M. The mineralocorticoid receptor mediates aldosterone-induced differentiation of T37i cells into brown adipocytes. Am J Physiol Endocrinol Metab 2000;279(2):E386-94.
7. Viengchareun S, Penfornis P, Zennaro MC, Lombes M. Mineralocorticoid and glucocorticoid receptors inhibit UCP expression and function in brown adipocytes. Am J Physiol Endocrinol Metab 2001;280(4):E640-9.
8. Funder J. Mineralocorticoids and cardiac fibrosis: the decade in review. Clin Exp Pharmacol Physiol 2001;28(12):1002-6.
9. Taddei S, Virdis A, Mattei P, Salvetti A. Vasodilation to acetylcholine in primary and secondary forms of human hypertension. Hypertension 1993;21(6 Pt 2):929-33.
10. Brilla CG, Weber KT. Mineralocorticoid excess, dietary sodium, and myocardial fibrosis. J Lab Clin Med 1992;120(6):893-901.
11. Connell JM, Davies E. The new biology of aldosterone. J Endocrinol 2005;186(1):1-20.
12. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999;341(10):709-17.
13. Pitt B, Stier CT Jr, Rajagopalan S. Mineralocorticoid receptor blockade: new insights into the mechanism of action in patients with cardiovascular disease. J Renin Angiotensin Aldosterone Syst 2003;4(3):164-8.
14. Zennaro MC, Lombes M. Mineralocorticoid resistance. Trends Endocrinol Metab 2004;15(6):264-70.
15. Pearce D, Bhargava A, Cole TJ. Aldosterone: its receptor, target genes, and actions. Vitam Horm 2003;66:29-76.
16. Farman N, Rafestin-Oblin ME. Multiple aspects of mineralocorticoid selectivity. Am J Physiol Renal Physiol 2001;280(2):F181-92.
17. Verrey F, Pearce D, Pfeiffer R, Spindler B, Mastroberardino L, Summa V, et al. Pleiotropic action of aldosterone in epithelia mediated by transcription and post-transcription mechanisms. Kidney Int 2000;57(4):1277-82.
18. Spindler B, Mastroberardino L, Custer M, Verrey F. Characterization of early aldosterone-induced RNAs identified in A6 kidney epithelia. Pflugers Arch 1997;434(3):323-31.
19. Naray-Fejes-Toth A, Canessa C, Cleaveland ES, Aldrich G, Fejes-Toth G. Sgk is an aldosterone-induced kinase in the renal collecting duct. Effects on epithelial Na+ channels. J Biol Chem 1999;274(24):16973-8.
20. Bhargava A, Fullerton MJ, Myles K, Purdy TM, Funder JW, Pearce D, et al. The serum- and glucocorticoid-induced kinase is a physiological mediator of aldosterone action. Endocrinology 2001;142(4):1587-94.
21. Robert-Nicoud M, Flahaut M, Elalouf JM, Nicod M, Salinas M, Bens M, et al. Transcriptome of a mouse kidney cortical collecting duct cell line: effects of aldosterone and vasopressin. Proc Natl Acad Sci USA 2001;98(5):2712-6.
22. Boulkroun S, Fay M, Zennaro MC, Escoubet B, Jaisser F, Blot-Chabaud M, et al. Characterization of rat NDRG2 (N-Myc downstream regulated gene 2), a novel early mineralocorticoid-specific induced gene. J Biol Chem 2002;277(35):31506-15.
23. Le Menuet D, Viengchareun S, Muffat-Joly M, Zennaro MC, Lombes M. Expression and function of the human mineralocorticoid receptor: lessons from transgenic mouse models. Mol Cell Endocrinol 2004;217(1-2):127-36.
24. Gormley K, Dong Y, Sagnella GA. Regulation of the epithelial sodium channel by accessory proteins. Biochem 2003;371(Pt 1):1-14.
25. Funder J. The nongenomic actions of aldosterone. Endocr Rev 2005;26(3):313-21.
26. Cheek DB, Perry JW. A salt wasting syndrome in infancy. Arch Dis Child 1958;33(169):252-6.
27. Geller DS, Rodriguez-Soriano J, Vallo Boado A, Schifter S, Bayer M, Chang SS, et al. Mutations in the mineralocorticoid receptor gene cause autosomal dominant pseudohypoaldosteronism type I. Nat Genet 1998;19(3):279-81.
28. Kuhnle U, Nielsen MD, Tietze HU, Schroeter CH, Schlamp D, Bosson D, et al. Pseudohypoaldosteronism in eight families: different forms of inheritance are evidence for various genetic defects. J Clin Endocrinol Metab 1990;70(3):638-41.
29. Armanini D, Wehling M, Da Dalt L, Zennaro M, Scali U, Keller U, et al. Pseudohypoaldosteronism and mineralocorticoid receptor abnormalities. J Steroid Biochem Mol Biol 1991;40(1-3):363-5.
30. Hanukoglu A. Type I pseudohypoaldosteronism includes two clinically and genetically distinct entities with either renal or multiple target organ defects. J Clin Endocrinol Metab 1991;73(5):936-44.
31. Hanukoglu A, Bistritzer T, Rakover Y, Mandelberg A. Pseudohypoaldosteronism with increased sweat and saliva electrolyte values and frequent lower respiratory tract infections mimicking cystic fibrosis. J Pediatr 1994;125(5 Pt 1):752-5.
32. Oberfield SE, Levine LS, Carey RM, Bejar R, New MI. Pseudohypoaldosteronism: multiple target organ unresponsiveness to mineralocorticoid hormones. J Clin Endocrinol Metab 1979;48(2):228-34.
33. Savage MO, Jefferson IG, Dillon MJ, Milla PJ, Honour JW, Grant DB. Pseudohypoaldosteronism: severe salt wasting in infancy caused by generalized mineralocorticoid unresponsiveness. J Pediatr 1982;101(2):239-42.
34. Bosson D, Kuhnle U, Mees N, Ramet J, Vamos E, Vertongen F, et al. Generalized unresponsiveness to mineralocorticoid hormones: familial recessive pseudohypoaldosteronism due to aldosterone-receptor deficiency. Acta Endocrinol Suppl (Copenh) 1986;279:376-80.
35. Chang SS, Grunder S, Hanukoglu A, Rosler A, Mathew PM, Hanukoglu I, et al. Mutations in subunits of the epithelial sodium channel cause salt wasting with hyperkalaemic acidosis, pseudohypoaldosteronism type 1. Nature Genet 1996;12:248-53.
36. Strautnieks SS, Thompson RJ, Gardiner RM, Chung E. A novel splice-site mutation in the gamma subunit of the epithelial sodium channel gene in three pseudohypoaldosteronism type 1 families. Nature Genet 1996;13:248-50.
37. Arai K, Zachman K, Shibasaki T, Chrousos GP. Polymorphisms of amiloride-sensitive sodium channel subunits in five sporadic cases of pseudohypoaldosteronism: do they have pathologic potential? J Clin Endocrinol Metab 1999;84:2434-7.
38. Adachi M, Tachibana K, Asakura Y, Abe S, Nakae J, Tajima T, et al. Compound heterozygous mutations in the gamma subunit gene of ENaC (1627delG and 1570-1G - >A) in one sporadic Japanese patient with a systemic form of pseudohypoaldosteronism type 1. J Clin Endocrinol Metab 2001;86(1):9-12.
39. Kellenberger S, Schild L. Epithelial sodium channel/degenerin family of ion channels: a variety of functions for a shared structure. Physiol Rev 2002;82(3):735-67.
40. Rossier BC, Canessa CM, Schild L, Horisberger JD. Epithelial sodium channels. Curr Opin Nephrol Hypertens 1994;3(5):487-96.
41. Horisberger JD, Canessa CM, Rossier BC. The epithelial sodium channel recent developments. Cell Physiol Biochem 1993;32:283-94.
42. Canessa CM, Schild L, Buell G, Thorens B, Gautschi I, Horisberger JD, et al. Amiloride-sensitive epithelial Na+ channel is made of three homologous subunits. Nature 1994;367(6462):463-7.
43. Kerem E, Bistritzer T, Hanukoglu A, Hofmann T, Zhou Z, Bennett W, et al. Pulmonary epithelial sodium-channel dysfunction and excess airway liquid in pseudohypoaldosteronism. N Engl J Med 1999;341(3):156-62.
44. Schaedel C,Marthinsen L, Kristoffersson AC, Kornfalt R, Nilsson KO, Orlenius B, et al. Lung symptoms in pseudohypoaldosteronism type 1 are associated with deficiency of the alpha-subunit of the epithelial sodium channel. J Pediatr 1999;135(6):739-45.
45. Saxena A, Hanukoglu I, Saxena D, Thompson RJ, Gardiner RM, Hanukoglu A. Novel mutations responsible for autosomal recessive multisystem pseudohypoaldosteronism and sequence variants in epithelial sodium channel alpha-, beta-, and gamma-subunit genes. J Clin Endocrinol Metab 2002;87(7):3344-50.
46. Bonny O, Knoers N, Monnens L, Rossier BC. A novel mutation of the epithelial Na+ channel causes type 1 pseudohypoaldosteronism. Pediatr Nephrol 2002;17(10):804-8.
47. Tajima T, Kitagawa H, Yokoya S, Tachibana K, Adachi M, Nakae J, et al. A novel missense mutation of mineralocorticoid receptor gene in one Japanese family with a renal form of pseudohypoaldosteronism type 1. J Clin Endocr Metab 2000;85:4690-4.
48. Viemann M, Peter M, Lopez-Siguero JP, Simic-Schleicher G, Sippell WG. Evidence for genetic heterogeneity of pseudohypoaldosteronism type 1: identification of a novel mutation in the human mineralocorticoid receptor in one sporadic case and no mutations in two autosomal dominant kindreds. J Clin Endocr Metab 2001;86:2056-9.
49. Riepe FG, Krone N, Morlot M, Ludwig M, Sippell WG, Partsch CJ. Identification of a novel mutation in the human mineralocorticoid receptor gene in a German family with autosomal-dominant pseudohypoaldosteronism type 1: further evidence for marked interindividual clinical heterogeneity. J Clin Endocrinol Metab 2003;88(4):1683-6.
50. Nystrom AM, Bondeson ML, Skanke N, Martensson J, Stromberg B, Gustafsson J, et al. A novel nonsense mutation of the mineralocorticoid receptor gene in a Swedish family with pseudohypoaldosteronism type I (PHA1). J Clin Endocrinol Metab 2004;89(1):227-31.
51. Riepe FG, Krone N, Morlot M, Peter M, Sippell WG, Partsch CJ. Autosomal-dominant pseudohypoaldosteronism type 1 in a Turkish family is associated with a novel nonsense mutation in the human mineralocorticoid receptor gene. J Clin Endocrinol Metab 2004;89(5):2150-2.
52. Geller DS, Zhang J, Zennaro MC, Vallo-Boado A, Rodriguez-Soriano J, Furu L, et al. Autosomal dominant pseudohypoaldosteronism type 1: mechanisms, evidence for neonatal lethality, and phenotypic expression in adults. J Am Soc Nephrol 2006;17(5):1429-36.
53. Sartorato P, Cluzeaud F, Fagart J, Viengchareun S, Lombes M, Zennaro MC. New naturally occurring missense mutations of the human mineralocorticoid receptor disclose important residues involved in dynamic interactions with deoxyribonucleic acid, intracellular trafficking, and ligand binding. Mol Endocrinol 2004;18(9):2151-65.
54. Schulz-Baldes A, Berger S, Grahammer F, Warth R, Goldschmidt I, Peters J, et al. Induction of the epithelial Na+ channel via glucocorticoids in mineralocorticoid receptor knockout mice. Pflugers Arch 2001;443(2):297- 305.
55. Benchimol C, Zavilowitz B, Satlin LM. Developmental expression of ROMK mRNA in rabbit cortical collecting duct. Pediatr Res 2000;47(1):46-52.
56. Evans WH, Bergeron JJ. Nuclear receptors: a re-evaluation. Trends Biochem Sci 1988;13(1):7-8.
57. Danielian PS, White R, Lees JA, Parker MG. Identification of a conserved region required for hormone dependent transcriptional activation by steroid hormone receptors. EMBO J 1992;11(3):1025-33.
58. Mangelsdorf DJ, Thummel C, Beato M, Herrlich P, Schutz G, Umesono K, et al. The nuclear receptor superfamily: the second decade. Cell 1995;83(6):835-9.
59. Zennaro MC, Keightley MC, Kotelevtsev Y, Conway GS, Soubrier F, Fuller PJ. Human mineralocorticoid receptor genomic structure and identification of expressed isoforms. J Biol Chem 1995;270(36):21016-20.
60. Pascual-Le Tallec L, Lombes M. The mineralocorticoid receptor: a journey exploring its diversity and specificity of action. Mol Endocrinol 2005;19(9):2211-21.
61. Arai K, Nakagomi Y, Iketani M, Shimura Y, Amemiya S, Ohyama K, et al. Functional polymorphisms in the mineralocorticoid receptor and amirolide-sensitive sodium channel genes in a patient with sporadic pseudohypoaldosteronism. Hum Genet 2003;112(1):91-7.
62. Arai K, Tsigos C, Suzuki Y, Irony I, Karl M, Listwak S, et al. Physiological and molecular aspects of mineralocorticoid receptor action in pseudohypoaldosteronism: a responsiveness test and therapy. J Clin Endocrinol Metab 1994;79(4):1019-23.
63. Geller DS, Farhi A, Pinkerton N, Fradley M, Moritz M, Spitzer A, et al. Activating mineralocorticoid receptor mutation in hypertension exacerbated by pregnancy. Science 2000;289(5476):119-23.
64. Fernandes-Rosa FL, de Castro M, Latronico AC, Sippell W, Riepe FG, Antonini SR. Recurrence of the R947X mutation in unrelated families with autosomal dominant pseudohypoaldosteronism type 1: evidence for a mutational hot spot in the mineralocorticoid receptor gene. J Clin Endocrinol Metab 2006;91(9):3671-5.